Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive Immunotherapy with Tyrosinase-Specific T Cells in Metastatic Melanoma
NCT00002786Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Oct 1995
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous CD8+ tyrosinase-specific T cells in melanoma, sponsored by Fred Hutchinson Cancer Center. Started Oct 1995; status: completed.
02
Drugs
autologous CD8+ tyrosinase-specific T cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00002786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002786.